ANIX Stock Forecast & Price Target

Anixa Biosciences Inc. has demonstrated a robust clinical performance in its CAR-T therapeutic programs, with a patient experiencing long-term survival exceeding 21 months following treatment and additional patients indicating promising outcomes, highlighting the therapy's potential in addressing solid tumor challenges. The company has outlined significant achievements for 2024, including positive clinical trial data and continued progress in its breast cancer vaccine and CAR-T therapy programs, positioning itself well for future growth and impact in oncology. Furthermore, the approved protocol amendment for the Phase 1 trial enhances the potential efficacy of the CAR-T therapy by allowing additional doses, thereby expanding the target population and bolstering Anixa's strategic objectives moving into 2025.

Anixa Biosciences Inc. is projected to experience significant financial challenges, as evidenced by a net loss of $12.6 million for fiscal year 2024, which translates to a loss of $0.39 per share. This persistent loss indicates ongoing difficulties in achieving profitability while the company invests heavily in its oncology-focused research and product development. Additionally, the substantial deficit raises concerns about the sustainability of its operations and the potential for future funding challenges.